Studies of HER2 positive breast cancer cell lines have demonstrated ibrutinib causes reduction in phosphorylation of EGFR, HER2 and human epidermal growth factor receptor 3 (HER3) [30], effects that are off-target to its original purpose in BTK inhibition. This evidence concerns the gene ERBB2 and breast carcinoma.